EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glutaredoxin‐1 promotes lymphangioleiomyomatosis progression through inhibiting Bim‐mediated apoptosis via COX2/PGE2/ERK pathway

Ya Feng, Tianjiao Li, Yin Li, Zhoujun Lin, Xiao Han, Xiaolin Pei, Yupeng Zhang, Fei Li, Juan Yang, Di Shao, Chenggang Li iD

Clinical and Translational Medicine · 2023

DOI: 10.1002/ctm2.1333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Ya Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, P. R. China. Hauptthemen laut MEDLINE: Lymphangioleiomyomatosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lymphangioleiomyomatosis (LAM) is a female‐predominant interstitial lung disease, characterized by progressive cyst formation and respiratory failure. Clinical treatment with the mTORC1 inhibitor rapamycin could relieve partially the respiratory symptoms, but not curative. It is urgent to illustrate the fundamental mechanisms of TSC2 deficiency to the development of LAM, especially mTORC1‐independent mechanisms. Glutaredoxin‐1 (Glrx), an essential glutathione (GSH)‐dependent thiol‐oxidoreductase, maintains redox homeostasis and participates in various processes via controlling protein GSH adducts. Redox signalling through protein GSH adducts in LAM remains largely elusive. Here, we demonstrate the underlying mechanism of Glrx in the pathogenesis of LAM.

Methods

1. Abnormal Glrx expression in various kinds of human malignancies was identified by the GEPIA tumour database, and the expression of Glrx in LAM‐derived cells was detected by real‐time quantitative reverse transcription (RT‐qPCR) and immunoblot. 2. Stable Glrx knockdown cell line was established to evaluate cellular impact. 3. Cell viability was determined by CCK8 assay. 4. Apoptotic cell number and intracellular reactive oxygen species (ROS) level were quantified by flow cytometry. 5. Cox2 expression and PGE2 production were detected to clarify the mechanism of Bim expression modulated by Glrx. 6. S‐glutathionylated p65 was enriched and detected by immunoprecipitation and the direct regulation of Glrx on p65 was determined. 7. The xenograft animal model was established and photon flux was analyzed using IVIS Spectrum.

Results

In LAM, TSC2 negatively regulated abnormal Glrx expression and activation in a mTORC1‐independent manner. Knockdown of Glrx increased the expression of Bim and the accumulation of ROS, together with elevated S‐glutathionylated proteins, contributing to the induction of apoptotic cell death and inhibited cell proliferation. Knockdown of Glrx in TSC2‐deficient LAM cells increased GSH adducts on nuclear factor‐kappa B p65, which contributed to a decrease in the expression of Cox2 and the biosynthesis of PGE2. Inhibition of PGE2 metabolism attenuated phosphorylation of ERK, which led to the accumulation of Bim, due to the imbalance of its phosphorylation and proteasome degradation. In xenograft tumour models, knockdown of Glrx in TSC2‐deficient LAM cells inhibited tumour growth and increased tumour cell apoptosis.

Conclusions

Collectively, we provide a novel redox‐dependent mechanism in the pathogenesis of LAM and propose that Glrx may be a beneficial strategy for the treatment of LAM or other TSC‐related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangioleiomyomatosisAnimalsHumansFemaleCyclooxygenase 2DinoprostoneTumor Suppressor ProteinsTuberous Sclerosis Complex 2 ProteinMAP Kinase Signaling SystemReactive Oxygen SpeciesGlutaredoxinsApoptosisMechanistic Target of Rapamycin Complex 1

Stichwörter der Autor:innen

Bimapoptosisglutaredoxinlymphangioleiomyomatosisoxidative stress

Substanzen

Cyclooxygenase 2DinoprostoneTumor Suppressor ProteinsTuberous Sclerosis Complex 2 ProteinReactive Oxygen SpeciesGlutaredoxinsMechanistic Target of Rapamycin Complex 1

Autor:innen und Institutionen

  • State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, P. R. China.
  • Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing, P. R. China.

ORCID-Profile: Chenggang Li

Förderung

  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Feng, Y., Li, T., Li, Y., Lin, Z., Han, X., Pei, X., Zhang, Y., Li, F., Yang, J., Shao, D., & Li, C. (2023). Glutaredoxin‐1 promotes lymphangioleiomyomatosis progression through inhibiting Bim‐mediated apoptosis via COX2/PGE2/ERK pathway. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1333

Vancouver

Feng Y, Li T, Li Y, Lin Z, Han X, Pei X, et al. Glutaredoxin‐1 promotes lymphangioleiomyomatosis progression through inhibiting Bim‐mediated apoptosis via COX2/PGE2/ERK pathway. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1333

BibTeX
@article{Feng2023,
  author = {Feng, Ya and Li, Tianjiao and Li, Yin and Lin, Zhoujun and Han, Xiao and Pei, Xiaolin and Zhang, Yupeng and Li, Fei and Yang, Juan and Shao, Di and Li, Chenggang},
  title = {Glutaredoxin‐1 promotes lymphangioleiomyomatosis progression through inhibiting Bim‐mediated apoptosis via COX2/PGE2/ERK pathway},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  doi = {10.1002/ctm2.1333}
}
Kostenlos starten →